Sepsis is a leading cause of morbidity and mortality in intensive care units. Sepsis is a
life-threatening organ dysfunction linked to a dysregulated host response to infection. It
leads to overwhelming of systemic inflammation causing release of proinflammatory cytokines,
which trigger overproduction of reactive oxygen species. Several animal studies with sepsis
proved the effectiveness of montelukast and coenzyme Q10 as anti-inflammatory and
antioxidants in preventing end organ damage, deterioration, and reducing mortality.
Therefore, a clinical trial will be carried out to compare the efficacy and safety of
montelukast versus co enzyme Q10 on the clinical outcome in patients with sepsis.